caa a22 4500 465737773 CHVBK 20180323111759.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF02253732 doi (NATIONALLICENCE)springer-10.1007/BF02253732 Spealman Roger Harvard Medical School, New England Regional Primate Research Center, 01772, Southborough, MA, USA aut Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers [Elektronische Daten] [Roger Spealman] The cocaine-antagonist effects of SCH 39166, which selectively blocks D1 dopamine receptors, were compared with those of YM 09151-2, a selective D2 receptor blocker, and flupenthixol, a nonselective blocker of both dopamine receptor subtypes. Squirrel monkeys were studied under a fixed-interval schedule of stimulus-shock termination, and the effects of cumulative doses of cocaine were determined alone and after pretreatment with each dopamine receptor blocker. When administered alone, cocaine (0.01-1.78 mg/kg, IV) had biphasic effects on responding: intermediate doses increased response rate, whereas higher doses decreased response rate. The ED50 for cocaine (average does that produced a half-maximal increase in response rate) was 0.04 mg/kg. Pretreatment with SCH 39166 (0.03 and 0.1 mg/kg, IV) resulted in surmountable antagonism of both the rate-increasing and rate-decreasing effects of cocaine, the ED50 being increased by as much as 13-fold. Similar effects were observed after pretreatment with YM 09151-2 (0.001 and 0.003 mg/kg, IV) and flupenthixol (0.01 and 0.03 mg/kg, IV), which respectively produced up to a 13-fold and 32-fold increase in ED50. There also was evidence for reciprocal antagonism of the rate-decreasing effects of the three dopamine receptor blockers by cocaine. The results suggest a prominent role for D1 as well as D2 dopamine receptors in mediating the effects of cocaine on schedule-controlled behavior. Springer-Verlag, 1990 Cocaine nationallicence Behavioral effects nationallicence Antagonism nationallicence Dopamine receptors nationallicence Squirrel monkeys nationallicence Psychopharmacology Springer-Verlag 101/1(1990-05-01), 142-145 0033-3158 101:1<142 1990 101 213 https://doi.org/10.1007/BF02253732 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02253732 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Spealman Roger Harvard Medical School, New England Regional Primate Research Center, 01772, Southborough, MA, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 101/1(1990-05-01), 142-145 0033-3158 101:1<142 1990 101 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer